

頭頸癌診療指引

一、參與討論同仁

附設醫院	吳家佑醫師	林哲玄醫師
	陳彥均醫師	陳盛鈺醫師
	郭嘉駿醫師	丁禮莉醫師
	林安沁個管師	
萬芳醫院	吳正友醫師	殷碩韓個管師
雙和醫院	蔡若婷醫師	鄭偉宏醫師
	王興萬醫師	黃金聲醫師
	何豫涵個管師	

二、討論日期：114 年 10 月 24 日

三、校稿人員：吳家佑醫師 / 林安沁個管師

114 年版	115 年修訂版
《口腔癌診療指引共識-2》 ● 主要治療： 1. 前導性化學治療 + 放射線治療 ± 輔助性化學治療 2. 前導性化學治療 + 同步化放療 ± 輔助性化學治療前導性化療 3. 前導性化療 ● 病理 (為主) 或影像發現 - 殘存腫瘤 * → 可手術且同意開刀者 - 殘存腫瘤 * → 無法切除或不願意手術者	《口腔癌診療指引共識檢查內容》 ● 選擇性檢查：PD-L1 (CPS) 檢測 ● 新增輔助治療： - 腫瘤已控制 → 同步化學及放射治療或近接治療或輔助性化學治療或手術或標靶治療
《口腔癌診療指引共識檢查內容》 《口咽癌診療指引共識-1》 ● 必要檢查：語言及吞嚥評估 ● 選擇性檢查：上消化道鏡 (如果有吸菸或喝酒)	《口咽癌診療指引共識-1》 ● 選擇性檢查：PD-L1 (CPS) 檢測
《喉癌診療指引共識-1》 ● 必要檢查：牙科會診 (放射線治療前 cT1-T2,N0 的病人除外) ● 選擇性檢查：上消化道鏡 (如果有吸菸或喝酒)	《喉癌診療指引共識-1》 ● 選擇性檢查：PD-L1 (CPS) 檢測

114 年版

115 年修訂版

《鼻咽癌診療指引共識 -1》

- 選擇性檢查：NGS profiling biomarker testing


《頭頸癌診療指引追蹤流程》

新增鼻咽癌 療程結束追蹤 EBV DNA

- 新增
- 口腔癌 / 口咽癌 / 喉癌 / 下咽癌 備註
- 若 CPS ≥ 1 ：建議術前 pembrolizumab/ 術後輔助治療建議：RT + pembrolizumab (如 ENE 或 positive margin 再合併 cisplatin)，完成後再給予 adjuvant pembrolizumab。

《下咽癌診療指引共識 -1》

- 選擇性檢查：PD-L1 (CPS) 檢測



* 病理 (為主) 或影像發現


*1 病理危險因子: 手術邊緣殘存腫瘤、淋巴囊外擴散、第二或第三級淋巴轉移 (N2 or N3 nodal disease)、第三或第四級腫瘤 (pT3 or pT4 primary)、第四或第五區淋巴結轉移 (nodal disease in Levels IV or V)、血管淋巴管侵犯、神經旁侵犯 (註)、Type V - WPOI

*2 無病理危險因子: T1-T2,N1 → 觀察 or 放射線治療 註: 在 T1-T2 若只有單一此項危險因子為選擇性治療


*3 對於手術切除邊緣仍有腫瘤細胞, 如果可能, 考慮再切除以達到邊緣無腫瘤。

備註: 若 CPS ≥ 1: 建議術前 pembrolizumab/ 術後輔助治療建議: RT + pembrolizumab (如 ENE 或 positive margin 再合併 cisplatin), 完成後再給予 adjuvant pembrolizumab。


《口腔癌診療指引共識 -2》




《 口腔癌診療指引共識檢查內容 》



《下咽癌診療指引共識 -1》






* LN ≥ 6cm 或 central necrosis 先行性頸部淋巴廓清術→同步化學及放射治療或同步標靶及放射治療

* 1 Extranodal extension, positive margins, close margins, pT3 or pT4 primary, pN2 or pN3 nodal disease, nodal disease in levels IV or V, perineural invasion, lymphovascular invasion

* 2 consider re-resection to achieve negative margins for positive resection margins if feasible

* 病理 (為主) 或影像發現

《下咽癌診療指引共識 -3》



* LN ≥ 6cm 或 central necrosis 先行性頸部淋巴廓清術→同步化學及放射治療或同步標靶及放射治療

* 1 Extranodal extension, positive margins, close margins, pT3 or pT4 primary, pN2 or pN3 nodal disease, nodal disease in levels IV or V, perineural invasion, lymphovascular invasion

* 2 consider re-resection to achieve negative margins for positive resection margins if feasible

* 3 病理 (為主) 或影像發現

檢查

臨床分期

主要治療

病理 (為主) 或影像發現

輔助治療

追蹤

必要檢查

- 活體組織檢查 (P16)
- 喉鏡
- 胸部放射線檢查
- 頭頸部磁共振造影或電腦斷層掃描
- 全身骨骼掃描 (初期疾病時為選擇性)
- 腹部超音波
- 語言及吞嚥評估
- 牙科會診 (放射線治療前)
- 聽力測量
- 營養會診

選擇性檢查

- 正子攝影掃描 (第三、四期疾病)
- 上消化道鏡 (如果有吸菸或喝酒)
- 支氣管鏡
- 篩檢 B 型肝炎
- PD-L1 (CPS) 檢測

T1-2, N0-1
or T0-2, N1

癌症分期請參考下表

切除原發腫瘤及同側或雙側頸部淋巴結廓清術 (視需要進行重建手術)

放射治療或同步化學及放射治療或同步標靶及放射治療 (for N0)

同步化學及放射線治療或同步標靶及放射治療 (for N1)

無病理危險因子

有病理危險因子¹

腫瘤已控制

殘餘腫瘤*

再切除陽性邊緣²或放射治療或同步化學及放射治療或同步標靶及放射治療

救援性手術 (若可切除)

見追蹤流程

P16 - T1N0(I), T2N0(II), T1N1(III), T2N1(III)

P16 + T1N0(I), T2N0(I), T1N1(I), T2N1(I)

* LN ≥ 6cm 或 central necrosis 先行性頸部淋巴結廓清術→同步化學及放射治療或同步標靶及放射治療


* 1 Extranodal extension, positive margins, close margins, pT3 or pT4 primary, pN2 or pN3 nodal disease, nodal disease in levels IV or V, perineural invasion, lymphovascular invasion

* 2 consider re-resection to achieve negative margins for positive resection margins if feasible

* 3 病理 (為主) 或影像發現

備註：若 CPS ≥ 1：建議術前 pembrolizumab/ 術後輔助治療建議：RT + pembrolizumab (如 ENE 或 positive margin 再合併 cisplatin)，完成後再給予 adjuvant pembrolizumab。

《口咽癌診療指引共識 -2》



檢查

臨床分期

主要治療

病理 (為主) 或影像發現

輔助治療


追蹤

必要檢查

- 活體組織檢查
- 咽喉鏡
- 胸部放射線檢查
- 頭頸部磁振造影或電腦斷層掃描
- 全身骨骼掃描 (初期疾病時為選擇性)
- 腹部超音波
- 牙科會診 (放射線治療前 cT1-T2, N0 的病人除外)
- 營養會診
- 語言及吞嚥評估

選擇性檢查

- 正子攝影掃描 (第三、四期疾病)
- 支氣管鏡
- 上消化道鏡 (如果有吸菸或喝酒)
- 聽力測量
- 肺功能檢查 (advanced T status is indicated)
- 篩檢 B 型肝炎
- PD-L1 (CPS) 檢測



* LN $\geq$ 6cm 或 central necrosis 先行性頸部淋巴廓清術→同步化學及放射治療或同步標靶及放射治療


* 1 Extranodal extension, positive margins, close margins, pT3 or pT4 primary, pN2 or pN3 nodal disease, nodal disease in levels IV or V, perineural invasion, lymphovascular invasion

* 2 consider re-resection to achieve negative margins for positive resection margins if feasible

* 3 病理 (為主) 或影像發現

備註: 若 CPS $\geq$ 1: 建議術前 pembrolizumab/ 術後輔助治療建議: RT + pembrolizumab (如 ENE 或 positive margin 再合併 cisplatin), 完成後再給予 adjuvant pembrolizumab。

《喉癌診療指引共識 -2》



* LN ≥ 6cm 或 central necrosis 先行性頸部淋巴廓清術→同步化學及放射治療或同步標靶及放射治療


* 1 Extranodal extension, positive margins, close margins, pT3 or pT4 primary, pN2 or pN3 nodal disease, nodal disease in levels IV or V, perineural invasion, lymphovascular invasion

* 2 consider re-resection to achieve negative margins for positive resection margins if feasible

* 3 病理 (為主) 或影像發現

備註：若 CPS ≥ 1：建議術前 pembrolizumab/ 術後輔助治療建議：RT + pembrolizumab (如 ENE 或 positive margin 再合併 cisplatin)，完成後再給予 adjuvant pembrolizumab。

檢查 臨床分期 主要治療 病理 (為主) 或影像發現 輔助治療 追蹤



* LN ≥ 6cm 或 central necrosis 先行性頸部淋巴廓清術 → 同步化學及放射治療或同步標靶及放射治療


* 1 Extranodal extension, positive margins, close margins, pT3 or pT4 primary, pN2 or pN3 nodal disease, nodal disease in levels IV or V, perineural invasion, lymphovascular invasion

* 2 consider re-resection to achieve negative margins for positive resection margins if feasible

* 3 病理 (為主) 或影像發現

備註：若 CPS ≥ 1：建議術前 pembrolizumab/ 術後輔助治療建議：RT + pembrolizumab (如 ENE 或 positive margin 再合併 cisplatin)，完成後再給予 adjuvant pembrolizumab。

《鼻咽癌診療指引共識 -1》



臨床追蹤頻率

- 治療後一年內，每個月追蹤一次
- 治療後第二年，每二到三個月追蹤一次
- 治療後第三年，每三個月追蹤一次
- 治療後第四、五年，每六個月追蹤一次

頭頸部磁共振造影或電腦斷層掃描

- 治療完成後3年內建議每3-6個月一次
- 治療完成後3年以後建議6-12個月一次

腹部超音波

- 治療完成後3年內建議每3-6個月一次
- 治療完成後3年以後建議6-12個月一次

正子攝影掃描及全身骨骼掃描及上消化道鏡檢查

- 臨床上必要時

鼻咽癌療程結束追蹤 EBV DNA

《參考文獻》

1. Al-Sarraf M, LeBlanc M, Giri PG, et al. Chemotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer : phase III randomized Intergroup study 0099. J Clin Oncol 1998; 16:1310-1317. Wee J, Tan EH, Tai BC, et al. Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union against cancer stage III and IV nasopharyngeal cancer of the endemic variety. J Clin Oncol 2005; 23 : 6730-6738.
2. NCCN Head and Neck Cancer Guidelines Version 5, 2025
3. Bernier J, Dumez C, Ozsahin M et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004; 350:1945-1952.
4. Budach W, Hehr T, Budach V, et al. A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck. BMC Cancer 2006; 6 : 28-38.
5. Chan AT, Leung SF, Ngan RK, et al. Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma. J Natl Cancer Inst 2005; 97: 536-539.
6. Chan AT, Hsu M-M, Goh BC, et al. Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. J Clin Oncol 2005; 23: 3568-3576.
7. Cooper JS, Pajak TF, Forastiere AA et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004; 350(19) : 1937-1944.
8. Hartford AC, Palosca MG, Eichler TJ, et al. American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) Practice Guidelines for Intensity-Modulated Radiation Therapy (IMRT). Int J Radiat Oncol Biol Phys 2009; 73: 9-14.

《頭頸癌抗癌藥物治療指引》

115 年版與上一版差異

114 年版 修訂日 113/12/30	115 年版 修訂日 114/12/08
Primary Systemic Therapy + Concurrent Radiotherapy	Primary Systemic Therapy + Concurrent Radiotherapy ■ 刪除 Paclitaxel + Cisplatin Q3W*6 ■ 刪除 Cisplatin + 5FU Q3W*6
Neoadjuvant immunotherapy	Neoadjuvant immunotherapy ■ 新增 Pembrolizumab + Cisplatin
Recurrent, Unresectable, or Metastatic Disease	Recurrent, Unresectable, or Metastatic Disease ■ 新增 Erdafitinib

《頭頸癌抗癌藥物治療指引》

Head and Neck (Non-Nasopharyngeal) Cancers

Lip, Oral Cavity, Oropharynx, Hypopharynx, Glottic Larynx, Supraglottic Larynx, Ethmoid Sinus, Maxillary Sinus, Occult Primary

Primary Systemic Therapy + Concurrent Radiotherapy

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Cisplatin	100	≥ 4 hrs	d1	Q3W	3	1, 2

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Cetuximab	400* → 250	90* → 60 mins	d1	QW	8	3

*1st dose 400 mg/m² then followed by 250 mg/m²

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Carboplatin	70	1 hr	d1-4	Q3W	3	4
5-FU	600	22-24 hrs	d1-4	Q3W	3	

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Carboplatin	70	1 hr	d1-5	Q4W	2	5
5-FU	600	22-24 hrs	d1-5	Q4W	2	

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
5-FU	800	22-24 hrs	d1-5	Q2W	6	6
Hydroxyurea	1g PO Q12H		11 doses	Q2W	6	

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Paclitaxel	30	≥ 1 hr	d1	QW	7	6
Cisplatin	20	≥ 1 hr	d2	QW	7	

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Cisplatin	100	≥ 4 hrs	d1	Q3W	3	7
5-FU	1000	22-24 hrs	d1-5	Q3W	3	

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Cisplatin	60	≥ 4 hrs	d1	Q2W	7	7
5-FU	800	22-24 hrs	d1-5	Q2W	7	

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Cisplatin	5	22-24 hrs	d1-4	Q4W	2	19
5-FU	250	22-24 hrs	d1-4	Q4W	2	

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Carboplatin	100	1 hr	d1	QW	8	8
Paclitaxel	40	≥ 1 hr	d1	QW	8	

藥品名	劑量 mg/m^2	輸注時間	給藥日	頻率	週期	參考文獻
Cisplatin	40	≥ 2 hrs	d1	QW	4	9, 10

藥品名	劑量 mg/m^2	輸注時間	給藥日	頻率	週期	參考文獻
Carboplatin	25	≥ 30 mins	d1-5	QW	5	16

藥品名	劑量 mg/m^2	輸注時間	給藥日	頻率	週期	參考文獻
Cisplatin	50	≥ 2 hrs	d1	Q2W	6	29
UFUR	800 mg* PO QD		d1-14	Q2W	6	
Leucovorin	60 mg PO QD		d1-14	Q2W	6	

*Or 300 mg/m^2

藥品名	劑量 mg/m^2	輸注時間	給藥日	頻率	週期	參考文獻
Cisplatin	80	≥ 4 hrs	d1	Q4W	2	30
5-FU	400	22-24 hrs	d1-4	Q4W	2	
Leucovorin	90	22-24 hrs	d1-4	Q4W	2	

Induction/Sequential Chemotherapy and Neoadjuvant Immunotherapy

藥品名	劑量 mg/m^2	輸注時間	給藥日	頻率	週期	參考文獻
Docetaxel	75	1 hr	d1	Q3W	3-4	22, 24
Cisplatin	75	≥ 4 hrs	d1	Q3W	3-4	
5-FU	750	22-24 hrs	d1-5	Q3W	3-4	

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Docetaxel	75	1 hr	d1	Q3W	3	23
Cisplatin	100	≥ 4 hrs	d1	Q3W	3	
5-FU	1000	22-24 hrs	d1-4 [#]	Q3W	3	

[#] May extend to day 5 if tolerable

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Cisplatin	80	≥ 4 hrs	d1	Q4W	3	30
5-FU	600	22-24 hrs	d1-4	Q4W	3	
Leucovorin	90	22-24 hrs	d1-4	Q4W	3	

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Paclitaxel	175	≥ 3 hrs	d1	Q3W	3	25
Cisplatin	100	≥ 4 hrs	d2	Q3W	3	
5-FU	500	22-24 hrs	d2-6	Q3W	3	

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Cetuximab	400* → 250	90* → 60 mins	d1	QW	6	8, 34
Paclitaxel	135	≥ 3 hrs	d1	QW	6	
Carboplatin	AUC 2	≥ 3 mins	d1	QW	6	

*1st dose 400 mg/m² then followed by 250 mg/m²

Stage III-IVa cancer (with PD-L1 (CPS) ≥ 1): Oral cavity, p 16-negative oropharynx, hypopharynx, and larynx**Neoadjuvant Pembrolizumab followed by adjuvant Pembrolizumab/RT (with Cisplatin if extranodal extension and/or positive margin) followed by adjuvant Pembrolizumab**

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Pembrolizumab	200 mg	≥ 30 mins	d1	Q3W	2	31, 32
Followed by Surgical tumor ablation						
Followed by						
Pembrolizumab	200 mg	≥ 30 mins	d1 of RT	Q3W	3 with RT	
± Cisplatin*	75	≥ 4 hrs	d1 of RT	Q3W	3 with RT	
Followed by						
Pembrolizumab	200 mg	≥ 30 mins	d1	Q3W	12	

*If extranodal extension and/or positive margin

Systemic Therapy/RT Following Induction Therapy, or Combination Chemotherapy for Recurrent/Persistent Disease

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Carboplatin	AUC 1.5	≥ 30 mins	d1	QW	7	26

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Cetuximab	400* → 250	90* → 60 mins	d1	QW	7	27

*1st dose 400 mg/m² then followed by 250 mg/m²

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Cisplatin	50	≥ 2 hrs	d1	Q2W	6	28
UFUR	800 mg* PO QD		d1-14	Q2W		
Leucovorin	60 mg PO QD		d1-14	Q2W		

*Or 300 mg/m²

Postoperative Chemoradiation

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Cisplatin	75-100	≥ 4 hrs	d1	Q3W	3	11-13, 15

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Cisplatin	30*	≥ 2 hrs	d1	QW	6	14, 33

*or 50 mg for 7-9 cycles with RT

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Cetuximab	400* → 250	90* → 60 mins	d1	QW	#	20
Cisplatin	30	≥ 2 hrs	d1	QW	#	

*1st dose 400 mg/m² then followed by 250 mg/m²

1st cycle before RT and continued cycles during RT

藥品名	劑量 mg/m^2	輸注時間	給藥日	頻率	週期	參考文獻
Cetuximab	400* → 250	90* → 60 mins	d1	QW	#	20
Docetaxel	15	≥ 30 mins	d1	QW	#	

*1st dose 400 mg/m^2 then followed by 250 mg/m^2

#1st cycle before RT and continued cycles during RT

參考文獻

1. Forastiere AA, Zhang Q, Weber RS, et al. Long-term results of radiotherapy OG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol 2013;31:845-852.
2. Adelstein DJ, Li Y, Adams GL, et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 2003;21(1):92-98.
3. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010;11:21-28.
4. Denis F, Garaud P, Bardet E, et al. Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol 2004;22:69-76.
5. Bourhis J, Sire C, Graff P, et al. Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label phase 3 randomised trial. Lancet Oncol 2012;13:145-153.
6. Garden AS, Harris J, Vokes EE, et al. Preliminary results of Radiation Therapy Oncology Group 97-03: A randomized phase II trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck. J Clin Oncol 2004;22:2856-2864.

7. Taylor S, Murthy A, Vannetzel J, et al. Randomized comparison of neoadjuvant cisplatin and fluorouracil infusion followed by radiation versus concomitant treatment in advanced head and neck cancer. *J Clin Oncol* 1994;12:385-395.
8. Suntharalingam M, Haas ML, Conley BA, et al. The use of carboplatin and paclitaxel with daily radiotherapy in patients with locally advanced squamous cell carcinomas of the head and neck. *Int J Radiat Oncol Biol Phys* 2000;47:49-56.
9. Beckmann GK, Hoppe F, Pfreundner L, et al. Hyperfractionated accelerated radiotherapy in combination with weekly cisplatin for locally advanced head and neck cancer. *Head Neck* 2005;27:36-43.
10. Medina JA, Rueda A, de Pasos AS, et al. A phase II study of concomitant boost radiation plus concurrent weekly cisplatin for locally advanced unresectable head and neck carcinomas. *Radiother Oncol* 2006;79:34-38
11. Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. *N Engl J Med* 2004;350:1937-1944
12. Bernier J, Dommenege C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. *N Engl J Med* 2004;350:1945-1952
13. Bernier J, Cooper JS, Pajak TF, et al. Defining risk levels in locally advanced head and neck cancers: A comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and radiotherapyOG (#9501). *Head Neck* 2005;27:843-850.
14. Bachaud JM, Cohen-Jonathan E, Alzieu C, et al. Combined postoperative radiotherapy and weekly cisplatin infusion for locally advanced head and neck carcinoma: final report of a randomized trial. *Int J Radiat Oncol Biol Phys* 1996 Dec 1;36:999-1004.
15. Cooper JS, Zhang Q, Pajak TF, et al. Long-term follow-up of the radiotherapyOG 9501/intergroup phase III trial: postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of the head and neck. *Int J Radiat Oncol Biol Phys* 2012;84:1198-1205.
16. Jeremic B, Milicic B, Dagovic A, et al. Radiation Therapy With or Without Concurrent Low-Dose Daily Chemotherapy in Locally Advanced, Nonmetastatic Squamous Cell Carcinoma of the Head and Neck. *J Clin Oncol*, 2004, 22:3540-3548

17. RTOG 0522: a randomized phase III trial of concurrent accelerated radiation and cisplatin versus concurrent accelerated radiation, cisplatin, and cetuximab [followed by surgery for selected patients] for Stage III and IV head and neck carcinomas. *Clin Adv Hematol Oncol* 2007;5: 79-81
18. Gibson MK, Li Y, Murphy B, et al. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. *J Clin Oncol* 2005;23:3562-3567
19. Soo KC, Tan EH, Wee J, et al. Surgery and adjuvant radiotherapy vs concurrent chemoradiotherapy in stage III/IV nonmetastatic squamous cell head and neck cancer: a randomised comparison. *Br J Cancer*. 2005;93:279-286
20. Harari PM, Harris J, Kies MS, et al. Postoperative chemoradiotherapy and cetuximab for high-risk squamous cell carcinoma of the head and neck: Radiation Therapy Oncology Group radiotherapy OG-0234. *J Clin Oncol*. 2014;32:2486-2495
21. Fietkau R, Lautenschläger C, Sauer R, et al. Postoperative concurrent radio-chemotherapy versus radiotherapy in high-risk SCCA of the head and neck: Results of the German phase III trial ARO 96–32006 ASCO Annual Meeting Proceedings (Post-Meeting Edition)24,(18S) 2006: 5507
22. Vermorken JB, Remenar E, van Herpen C, et al; EORTC 24971/TAX 323 Study Group. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. *N Engl J Med* 2007;357(17):1695-1704.
23. Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. *N Engl J Med* 2007;357(17):1705-1715
24. Pointreau Y, Garaud P, Chapet S, et al. Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. *J Natl Cancer Inst* 2009;101:498-506
25. Hitt R, López-Pousa A, Martínez-Trufero J, et al. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. *J Clin Oncol* 2005;23:8636-8645.
26. Haddad R, O'Neill A, Rabinowits G, et al. Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM):

- a randomised phase 3 trial. *Lancet Oncol.* 2013;14:257-4264
27. Lefebvre JL, Pointreau Y, Rolland F, et al. Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: the TREMPLIN randomized phase II study. *J Clin Oncol* 2013;31:853-859.
 28. Hung-Ming Wang, Cheng-Su Wang, Jen-Shi Chen, et al. Cisplatin, tegafur, and leucovorin: A moderately effective and minimally toxic outpatient neoadjuvant chemotherapy for locally advanced squamous cell carcinoma of the head and neck. *Cancer* 2002; 94 (11): 2982-2995.
 29. Wang HM, Hsu CL, Hsieh CH, et al. Concurrent chemoradiotherapy using cisplatin, tegafur, and leucovorin for advanced squamous cell carcinoma of the hypopharynx and oropharynx. *Biomed J* 2014;37(3):133-40.
 30. Chi KH, Chen CH, Chan WK, et al. Effect of granulocyte-macrophage colony-stimulating factor on oral mucositis in head and neck cancer patients after cisplatin, fluorouracil, and leucovorin chemotherapy. *J Clin Oncol.* 1995 Oct;13(10):2620-8. doi: 10.1200/JCO.1995.13.10.2620. PMID: 7595716.
 31. Uppaluri R, Haddad RI, Tao Y, et al. Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer. *N Engl J Med.* 2025;393(1):37-50. doi:10.1056/NEJMoa2415434
 32. Uppaluri R, Campbell KM, Egloff AM, et al. Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial. *Clin Cancer Res.* 2020;26(19):5140-5152. doi:10.1158/1078-0432.CCR-20-1695
 33. Noronha V, Joshi A, Patil VM, et al. Once-a-Week versus once-every-3-weeks cisplatin chemoradiation for Locally advanced head and neck cancer: a phase III randomized noninferiority trial. *J Clin Oncol* 2017;Jco2017749457.
 34. Kies MS, Holsinger FC, Lee JJ, et al. Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial. *J Clin Oncol* 2010;28:8-14.

Recurrent, Unresectable, or Metastatic (incurable) Disease

First-line Therapy

Combination Therapy

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Cetuximab	400* → 250	90* → 60 mins	d1	QW		1
Cisplatin	100	≥ 4 hrs	d1	Q3W	Max 6	
5-FU	1000	22-24 hrs	d1-4	Q3W	Max 6	

*1st dose 400 mg/m² then followed by 250 mg/m²

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Cetuximab	400* → 250	90* → 60 mins	d1	QW		1
Carboplatin	AUC 5	1 hr	d1	Q3W	Max 6	
5-FU	1000	22-24 hrs	d1-4	Q3W	Max 6	

*1st dose 400 mg/m² then followed by 250 mg/m²

Immunotherapy

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Pembrolizumab	200 mg	≥ 30 mins	d1	Q3W	34 (24 mo)	18
Cisplatin	100	≥ 4 hrs	d1	Q3W	6	
5-FU	1000	22-24 hrs	d1-4	Q3W	6	

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Pembrolizumab	200 mg	≥ 30 mins	d1	Q3W	34 (24 mo)	18
Carboplatin	AUC 5	1 hr	d1	Q3W	6	
5-FU	1000	22-24 hrs	d1-4	Q3W	6	

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Pembrolizumab	200 mg	≥ 30 mins	d1	Q3W	34 (24 mo)	18, 19

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Pembrolizumab	200 mg	≥ 30 mins	d1	Q3W	6	2, 20
Cisplatin	75-100	≥ 4 hrs	d1	Q3W	6	
Paclitaxel	175	≥ 3 hrs	d1	Q3W	6	

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Pembrolizumab	200 mg	≥ 30 mins	d1	Q3W	6	2, 20
Carboplatin	AUC 5	1 hr	d1	Q3W	6	
Paclitaxel	175	≥ 3 hrs	d1	Q3W	6	

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Pembrolizumab	200 mg	≥ 30 mins	d1	Q3W	6	2, 20
Cisplatin	100	≥ 4 hrs	d1	Q3W	6	
Docetaxel	65	1 hr	d1	Q3W	6	

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Pembrolizumab	200 mg	≥ 30 mins	d1	Q3W	6	2, 20
Carboplatin	AUC 5-6	1 hr	d1	Q3W	6	
Docetaxel	65	1 hr	d1	Q3W	6	

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Pembrolizumab	200 mg	≥ 30 mins	d1	Q3W		21
Cetuximab	400* → 250	90* → 60 mins	d1	QW		

*1st dose 400 mg/m² then followed by 250 mg/m²

Other Combination Therapy

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Docetaxel	65	1 hr	d1	Q3W		2
Carboplatin	AUC 6	1 hr	d1	Q3W		

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Paclitaxel	175	≥ 3 hrs	d1	Q3W		3
Cisplatin	75	≥ 4 hrs	d1	Q3W		

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Paclitaxel	175	≥ 4 hrs	d1	Q3W		3
Carboplatin	AUC 6	1 hr	d1	Q3W		

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Cetuximab	200* → 125	90* → 60 mins	d1	QW		4
Cisplatin	100	≥ 4 hrs	d1	Q4W	2-6	

*1st dose 200 mg/m² then followed by 125 mg/m²

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Cisplatin	100	≥ 4 hrs	d1	Q3W	Min 6	3, 5
5-FU	1000	22-24 hrs	d1-4	Q3W	Min 6	

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Cetuximab	400* → 250 → 500	90* → 60 mins	d1	QW* → QW → Q2W		6
Docetaxel	75	1 hr	d1	Q3W	4	
Cisplatin	75	≥ 4 hrs	d1	Q3W	4	

*1st dose 400 mg/m² and 2nd dose 250 mg/m² QW then followed by 500 mg/m² Q2W

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Cetuximab	400* → 250 → 500	90* → 60 mins	d1	QW* → QW → Q2W		15
Docetaxel	75	1 hr	d1	Q3W	4	
Carboplatin	AUC 5	1 hr	d1	Q3W	4	

*1st dose 400 mg/m² and 2nd dose 250 mg/m² QW then followed by 500 mg/m² Q2W

藥品名	劑量 mg/m^2	輸注時間	給藥日	頻率	週期	參考文獻
Cetuximab	400* → 250	90* → 60 mins	d1	QW		1
Cisplatin	100	≥ 4 hrs	d1	Q3W	Max 6	
5-FU	1000	22-24 hrs	d1-4	Q3W	Max 6	

*1st dose 400 mg/m^2 then followed by 250 mg/m^2

藥品名	劑量 mg/m^2	輸注時間	給藥日	頻率	週期	參考文獻
Cetuximab	400* → 250	90* → 60 mins	d1	QW		1
Carboplatin	AUC 5	1 hr	d1	Q3W	Max 6	
5-FU	1000	22-24 hrs	d1-4	Q3W	Max 6	

*1st dose 400 mg/m^2 then followed by 250 mg/m^2

藥品名	劑量 mg/m^2	輸注時間	給藥日	頻率	週期	參考文獻
Paclitaxel	175	≥ 3 hrs	d1	Q3W	2	16, 17
Cisplatin	75	≥ 4 hrs	d1	Q3W	2	
Followed by						
Cetuximab	400* → 250	90* → 60 mins	d1	QW		
Cisplatin	75	≥ 4 hrs	d1	Q3W	4	

*1st dose 400 mg/m^2 then followed by 250 mg/m^2

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Paclitaxel	175	≥ 3 hrs	d1	Q3W	2	16, 17
Carboplatin	AUC 6	1 hr	d1	Q3W	2	
Followed by						
Cetuximab	400* → 250	90* → 60 mins	d1	QW		
Carboplatin	AUC 6	1 hr	d1	Q3W	4	

*1st dose 400 mg/m² then followed by 250 mg/m²

Single Agents

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Cisplatin	100	≥ 4 hrs	d1	Q3-4W		7, 8

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Paclitaxel	80	≥ 3 hrs	d1	QW	6	9

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Docetaxel	100	1 hr	d1	Q3W		10

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
5-FU	1000	22-24 hrs	d1	Q3W		8

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Methotrexate	40	≥ 30 mins	d1	QW		11, 12

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Cetuximab	400* → 250	90* → 60 mins	d1	QW	Min 7	13

*1st dose 400 mg/m² then followed by 250 mg/m²

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Cetuximab	500	2 hrs	d1	Q2W	2	25

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Capecitabine	1250 PO BID	d1-14	Q3W	Min 2	14

Useful in Certain Circumstances

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Cetuximab	400* → 250	90* → 60 mins	d1, 8, 15	Q4W		23
Paclitaxel	80	≥ 1 hr	d1, 8, 15	Q4W		

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Cetuximab	500	2 hrs	d1	Q2W		24
Docetaxel	50	1 hr	d1	Q2W		

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Nivolumab	3 mg/kg	≥ 30 mins	d1	Q2W		22
Ipilimumab	1 mg/kg	≥ 30 mins	d1	Q6W		

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Fam-trastuzumab deruxtecan-nxki	5.4 mg/kg	90 mins	d1	Q3W		26

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Erdaftinib	8 mg PO QD				27

參考文獻

1. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008;359:1116-1127.
2. Samlowski WE, Moon J, Kuebler JP, et al. Evaluation of the combination of docetaxel/carboplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN): a Southwest Oncology Group Phase II study. Cancer Invest 2007;25:182-188.
3. Gibson MK, Li Y, Murphy B, et al. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): An Intergroup Trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2005;23:3562-3567.
4. Burtneess B, Goldwasser MA, Flood W, et al. Phase III randomized trial of cisplatin plus placebo versus cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: An Eastern Cooperative Oncology Group Study. J Clin Oncol 2005;23:8646-8654.
5. Forastiere AA, Metch B, Schuller DE, et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous cell carcinoma of the head and neck: A Southwest Oncology Group Study. J Clin Oncol 1992;10:1245-1251.
6. Guigay J, Fayette J, Dillies A-F, et al. Cetuximab, docetaxel, and cisplatin (TPEx) as first-line treatment in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): Final results of phase II trial

- GORTEC 2008-03 [abstract]. J Clin Oncol 2012;30(Suppl 15):Abstract 5505.
7. Burthese B, Goldwasser MA, Flood W, et al. Phase III Randomized Trial of Cisplatin Plus Placebo Compared With Cisplatin Plus Cetuximab in Metastatic/Recurrent Head and Neck Cancer: An Eastern Cooperative Oncology Group Study. J Clin Oncol 2005;23:8646-8654.
 8. Jacobs C, Lyman G, Velez-Garcia E, et al. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 1992;10:257-263.
 9. Grau JJ, Caballero M, Verger E, et al. Weekly paclitaxel for platin-resistant stage IV head and neck cancer patients. Acta OtoLaryngol 2009;129:1294-1299.
 10. Catimell G, Verweij J, Mattijssen V, et al. Docetaxel (Taxotere): An active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. Ann Oncol 1994;5:533-537.
 11. Stewart JS, Cohen EE, Licitra L, et al. Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]. J Clin Oncol 2009;27:1864-1871
 12. Forastiere AA, Metch B, Schuller DE, et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol. 1992 Aug;10(8):1245-51.
 13. Vermorken JB, Trigo J, Hitt R, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol. 2007 Jun 1;25(16):2171-7.
 14. Martinez-Trufero J, Isla D, Adansa JC, et al. Phase II study of capecitabine as palliative treatment for patients with recurrent and metastatic squamous head and neck cancer after previous platinum-based treatment. Br J Cancer 2010;102:1687-1691.
 15. Joel Guigay UK, Ricard Mesia, Nadejda Vintonenko, Jean Bourhis, Anne Auperin. TPExtreme randomized trial: TPEx versus Extreme regimen in 1st line recurrent/metastatic head and neck squamous cell carcinoma. Journal of Clinical Oncology 2015.
 16. Price KA, Cohen EE. Current treatment options for metastatic head and neck cancer. Curr Treat Options Oncol 2012;13:35-46.
 17. Herbst RS, Arquette M, Shin DM, et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol 2005;23:5578-5587.
 18. Rischin D, Harrington KJ, Greil R, et al. Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M

- HNSCC). *J Clin Oncol* 2019;37(suppl)6000-6000.
19. Burtneß B, Harrington KJ, Greil R, et al. KEYNOTE-048: Phase 3 study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). ESMO 2018 Congress
20. Burtneß B, Harrington KJ, Greil R, Soulières D, Tahara M, de Castro G, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. *Lancet*. (2019) 394:1915–28. doi: 10.1016/s0140-6736(19)32591-7
21. Sacco AG, Chen R, Worden FP, et al. Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial. *Lancet Oncol*. 2021 Jun;22(6):883-892.
22. Haddad RI, Harrington K, Tahara M, et al. Nivolumab plus ipilimumab versus EXTREME regimen as first-line treatment for recurrent/metastatic squamous cell carcinoma of the head and neck: Final results of CheckMate 651. *J Clin Oncol* 2023;41:2166-2180.
23. Okada T, Okamoto I, Sato H, Ito T, Miyake K, Tsukahara K. Efficacy and Safety of Paclitaxel Combined With Cetuximab for Head and Neck Squamous Cell Carcinoma. *In Vivo*. 2021 Mar-Apr;35(2):1253-1259. doi: 10.21873/invivo.12376. PMID: 33622928; PMCID: PMC8045122.
24. Posch D, Fuchs H, Kornek G, Grah A, Pammer J, Aretin MB, Fuehrer T. Docetaxel plus cetuximab biweekly is an active regimen for the first-line treatment of patients with recurrent/metastatic head and neck cancer. *Sci Rep*. 2016 Sep 6;6:32946. doi: 10.1038/srep32946. PMID: 27597175; PMCID: PMC5011715.
25. Fury MG, Sherman E, Lisa D, et al. A randomized phase II study of cetuximab every 2 weeks at either 500 or 750 mg/m² for patients with recurrent or metastatic head and neck squamous cell cancer. *J Natl Compr Canc Netw* 2012;10:1391-1398.
26. Meric-Bernstam F, Makker V, et al. Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial. *J Clin Oncol*. 2024 Jan 1;42(1):47-58. doi: 10.1200/JCO.23.02005. Epub 2023 Oct 23. PMID: 37870536; PMCID: PMC10730032.
27. Pant S, Schuler M, Iyer G, et al. Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study. *Lancet Oncol* 2023;24:925-935.

《 鼻咽癌抗癌藥物治療指引 》

115 年版與上一版差異

114 年版 修訂日 113/12/30	115 年版 修訂日 114/12/08
審視無異動	

《鼻咽癌抗癌藥物治療指引》

Nasopharynx Carcinoma

Chemoradiation Followed by Adjuvant Chemotherapy

Cisplatin + RT followed by Cisplatin/5-FU

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Cisplatin	100	≥ 4 hrs	d1	Q3W	3 with RT	1
Followed by						
Cisplatin	80	≥ 4 hrs	d1	Q4W	3 after RT	
5-FU	1000	22-24 hrs	d1-4	Q4W	3 after RT	

Carboplatin + RT followed by Carboplatin/5-FU

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Carboplatin	AUC 6	1 hr	1	Q3W	3-5 with RT	2
Followed by						
Carboplatin	AUC 5	1 hr	1	Q3W	2 after RT	
5-FU	1000	22-24 1 hrs	1-4	Q3W	2 after RT	

Cisplatin + RT without adjuvant chemotherapy

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Cisplatin	40	≥ 2 hrs	d1	QW	7	3

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Cisplatin	50	≥ 2 hrs	d1	Q2W	During RT	11
UFUR	800 mg* PO		d1-14	Q2W	During RT	
Leucovorin	60 mg PO		d1-14	Q2W	During RT	

*Or 300 mg/m²**After definitive chemoradiotherapy ± induction chemotherapy**

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Capecitabine	650 PO BID			For 1 year	17

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Cisplatin	80	≥ 4 hrs	d1	Q4W	2	18
5-FU	400	22-24 hrs	d1-4	Q4W	2	
Leucovorin	90	22-24 hrs	d1-4	Q4W	2	

Reirradiation + Concurrent Systemic Therapy**For patients with HF-IMRT**

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Cisplatin	100	≥ 4 hrs	d1	Q3W	3 before RT	15, 16
Gemcitabine	1000	30 mins	d1, 8	Q3W	3 before RT	
Followed by Cisplatin	40	≥ 2 hrs	d1	QW	6 with RT	

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Carboplatin	AUC 5	1 hr	d1	Q3W	3 before RT	15, 16
Gemcitabine	1000	30 mins	d1, 8	Q3W	3 before RT	
Followed by Cisplatin	40	≥ 2 hrs	d1	QW	6 with RT	

For patients with SF-IMRT

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Cisplatin	100	≥ 4 hrs	d1	Q3W	3 before RT	15, 16
5-Fu	1000	22-24 hrs	d1-4	Q3W	3 before RT	
Followed by Cisplatin	40	≥ 2 hrs	d1	QW	6 with RT	

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Carboplatin	AUC 5	1 hr	d1	Q3W	3 before RT	15, 16
5-Fu	1000	22-24 hrs	d1-4	Q3W	3 before RT	
Followed by Cisplatin	40	≥ 2 hrs	d1	QW	6 with RT	

Induction/Sequential Chemotherapy

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Cisplatin	80	≥ 4 hrs	d1	Q3W	3	14
Gemcitabine	1000	30 mins	d1, 8	Q3W	3	

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Docetaxel	70	1 hr	d1	Q3W	3	4
Cisplatin	75	≥ 4 hrs	d1	Q3W	3	
5-FU	1000	22-24 hrs	d1-4	Q3W	3	
Followed by Cisplatin	100	≥ 4 hrs	d1	Q3W	With RT	

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Docetaxel	60	1 hr	d1	Q3W	3	12
Cisplatin	60	≥ 4 hrs	d1	Q3W	3	
5-FU	600	22-24 hrs	d1-5	Q3W	3	
Followed by Cisplatin	100	≥ 4 hrs	d1	Q3W	With RT	

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Docetaxel	75	1 hr	d1	Q3W	2	5
Cisplatin	75	≥ 4 hrs	d1	Q3W	2	
Followed by Cisplatin	40	≥ 2 hrs	d1	QW	With RT	

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Cisplatin	100	≥ 4 hrs	d1	Q3W	3	6
5-FU	1000	22-24 hrs	d1-4	Q3W	3	

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Cisplatin	40	≥ 2 hrs	d1	QW	7 during RT	7

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Epirubicin	60-75	≥ 30 mins	d1	Q4W	3	8
Mitomycin	10	≥ 5 mins	d1	Q4W	Cycle 1, 3 only	
Cisplatin	60-100	≥ 4 hrs	d1	Q4W	3	

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Cisplatin	80	≥ 4 hrs	d1	Q4W	3	9
5-FU	1000	22-24 hrs	d1-4	Q4W	3	

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Cisplatin	80	≥ 4 hrs	d1	Q4W	2	18
5-FU	600	22-24 hrs	d1-4	Q4W	2	
Leucovorin	90	22-24 hrs	d1-4	Q4W	2	

Following induction, agents to be used with concurrent chemoradiation typically include weekly cisplatin or carboplatin

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Cisplatin	40	≥ 2 hrs	d1	QW	7	10

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Carboplatin	AUC 2	≥ 30 mins	d1	QW	6 (Max 7)	13

參考文獻

1. Al-Sarraf M, LeBlanc M, Giri PG, Fu KK, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. *J Clin Oncol*. 1998 ;16:1310-1317.
2. Dechaphunkul T, Pruegsanusak K, Sangthawan D, et al. Concurrent chemoradiotherapy with carboplatin followed by carboplatin and 5-fluorouracil in locally advanced nasopharyngeal carcinoma. *Head Neck Oncol*. 2011;3:30.
3. Chen L, Hu CS, Chen XZ, et al. Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial. *Lancet Oncol*. 2012;13:163-171.
4. Bae WK, Hwang JE, Shim HJ, et al. Phase II study of docetaxel, cisplatin, and 5-FU induction chemotherapy followed by chemoradiotherapy in locoregionally advanced nasopharyngeal cancer. *Cancer Chemother Pharmacol*. 2010;65:589-595.
5. Hui EP, Ma BB, Leung SF, et al. Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma. *J Clin Oncol*. 2009;27:242-249.
6. Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. *N Engl J Med* 2007;357(17):1705-1715.
7. A Hellenic Cooperative Oncology Group phase II study. *Strahlenther Onkol*. 2005;181:223-230.
8. Hong RL, Ting LL, Ko JY, et al. Induction chemotherapy with mitomycin, epirubicin, cisplatin, fluorouracil, and leucovorin followed by radiotherapy in the treatment of locoregionally advanced nasopharyngeal carcinoma. *J Clin Oncol*. 2001;19:4305-4313.
9. Muhyi al-Sarraf, Martine Leblanc, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. *J Clin Oncol* 1998; 16: 1310-1317.
10. Chan AT, Leung SF, Ngan RK, et al. Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma. *J Natl Cancer Inst*. 2005 Apr 6;97(7):536-539.
11. Concurrent chemoradiotherapy using biweekly cisplatin/tegafur plus uracil/leucovorin in stage III nasopharyngeal carcinoma. *J Clin Oncol*. 2005 23(16): 5510
12. Sun Y, Li WF, Chen NY, et al. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised

- controlled trial. *Lancet Oncol* 2016; 17: 1509–20.
13. Ou D, Blanchard P, Khoury CE, et al. Induction chemotherapy with docetaxel, cisplatin and fluorouracil followed by concurrent chemoradiotherapy or chemoradiotherapy alone in locally advanced non-endemic nasopharyngeal carcinoma. *Oral Oncology* 62 (2016) 114–121.
 14. Zhang Y, Chen L, Hu GQ, Zhang N, Zhu XD, Yang KY, et al. Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma. *N Engl J Med.* (2019) 381:1124–35.
 15. Lee VHF, Kwong DL, Leung T-W, et al. Hyperfractionation compared to standard fractionation in intensity-modulated radiation therapy for patients with locally advanced recurrent nasopharyngeal carcinoma. *Eur Arch Otorhinolaryngol* 2017;274:1067-1078.
 16. Kong F, Zhou J, Du C, et al. Long-term survival and late complications of intensity-modulated radiotherapy for recurrent nasopharyngeal carcinoma. *BMC Cancer* 2018;18:1139.
 17. Chen YP, Liu X, Zhou Q, et al. Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: A multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial. *Lancet* 2021;398:303-313.
 18. Chi KH, Chan WK, Cooper DL, Yen SH, Lin CZ, Chen KY. A phase II study of outpatient chemotherapy with cisplatin, 5-fluorouracil, and leucovorin in nasopharyngeal carcinoma. *Cancer.* 1994 Jan 15;73(2):247-52. doi: 10.1002/1097-0142(19940115)73:2<247::aid-cnrc2820730203>3.0.co;2-7. PMID: 8293384.

Recurrent, Unresectable, or Metastatic Disease

First-line Therapy

Preferred Regimens

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Cisplatin	20-30*	≥ 2 hrs	d1-3	Q3W	Max 6	5
Gemcitabine	1000	30 mins	d1, 8	Q3W	Max 6	

*80 mg/m² in divided doses on 3 days

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Pembrolizumab	200 mg	≥ 30 mins	d1	Q3W	4-6	18
Cisplatin	80	≥ 4 hrs	d1	Q3W	4-6	
Gemcitabine	1000	30 mins	d1, 8	Q3W	4-6	
Followed by Pembrolizumab	200 mg	≥ 30 mins	d1	Q3W		

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Nivolumab	240 mg	≥ 30 mins	d1	Q3W	4-6	19
Cisplatin	80	≥ 4 hrs	d1	Q3W	4-6	
Gemcitabine	1000	30 mins	d1, 8	Q3W	4-6	
Followed by Nivolumab	240 mg	≥ 30 mins	d1	Q3W		

Other Recommended Regimens

Combination Therapy

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Docetaxel	65	1 hr	d1	Q3W		1
Carboplatin	AUC 6	1 hr	d1	Q3W		

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Paclitaxel	175	≥ 3 hrs	d1	Q3W	Min 6	2
Cisplatin	75	≥ 4 hrs	d1	Q3W	Min 6	

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Carboplatin	AUC 6	1 hr	d1	Q3W	Min 6	2
Paclitaxel	175	≥ 3 hrs	d1	Q3W	Min 6	

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Cisplatin	100	≥ 4 hrs	d1	Q3W	Min 6	2, 3
5-FU	1000	22-24 hrs	d1-4	Q3W	Min 6	

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Cetuximab	400* → 250	90 → 60 mins	d1	QW	Max 8	4
Carboplatin	AUC 5	1 hr	d1	Q3W		

*1st dose 400 mg/m² then followed by 250 mg/m²

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Gemcitabine	1000	30 mins	d1, 8	Q3W	Max 8	15
Carboplatin	AUC 5	1 hr	d1	Q3W		

Cisplatin/gemcitabine + PD-1 inhibitor

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Pembrolizumab	200 mg	≥ 30 mins	d1	Q3W		16, 17
Cisplatin	80	≥ 4 hrs	d1	Q3W	4-6	
Gemcitabine	1000	30 mins	d1, 8	Q3W	4-6	

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Nivolumab	240 mg	≥ 30 mins	d1	Q3W		16, 17
Cisplatin	80	≥ 4 hrs	d1	Q3W	4-6	
Gemcitabine	1000	30 mins	d1, 8	Q3W	4-6	

Single Agents

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Cisplatin	100	≥ 4 hrs	d1	Q3-4W	Min 4	6, 7

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Carboplatin	AUC 6	1 hr	d1	Q3W		14

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Paclitaxel	80	≥ 1 hr	d1	QW	6	8

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Docetaxel	100	1 hr	d1	Q3W		9

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
5-FU	1000	22-24 hrs	d1	Q3W		7

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Methotrexate	40	≥ 30 mins	d1	QW		10, 11

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Gemcitabine	1000	30 mins	d1, 8, 15	Q4W		12

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Capecitabine	1250 PO BID	d1-14	Q3W	Min 2	13

參考文獻

1. Samlowski WE, Moon J, Kuebler JP, et al. Evaluation of the combination of docetaxel/carboplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN): a Southwest Oncology Group Phase II study. Cancer Invest 2007;25:182-188.
2. Gibson MK, Li Y, Murphy B, et al. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): An Intergroup Trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2005;23:3562-3567.

3. Forastiere AA, Metch B, Schuller DE, et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous cell carcinoma of the head and neck: A Southwest Oncology Group Study. *J Clin Oncol* 1992;10:1245-1251.
4. Chan AT, Hsu MM, Goh BC, et al. Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. *J Clin Oncol* 2005;23:3568-3576.
5. Jin Y, Cai XY, Shi YX, et al. Comparison of five cisplatin-based regimens frequently used as the first-line protocols in metastatic nasopharyngeal carcinoma. *J Cancer Res Clin Oncol* 2012 Oct;138(10):1717-25.
6. Burthese B, Goldwasser MA, Flood W, et al. Phase III Randomized Trial of Cisplatin Plus Placebo Compared With Cisplatin Plus Cetuximab in Metastatic/Recurrent Head and Neck Cancer: An Eastern Cooperative Oncology Group Study. *J Clin Oncol* 2005;23:8646-8654.
7. Jacobs C, Lyman G, Velez-Garcia E, et al. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. *J Clin Oncol* 1992;10:257-263.
8. Grau JJ, Caballero M, Verger E, et al. Weekly paclitaxel for platin-resistant stage IV head and neck cancer patients. *Acta OtoLaryngol* 2009;129:1294-1299.
9. Catimell G, Verweij J, Mattijssen V, et al. Docetaxel (Taxotere): An active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. *Ann Oncol* 1994;5:533-537.
10. Stewart JS, Cohen EE, Licitra L, et al. Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]. *J Clin Oncol* 2009;27:1864-1871
11. Forastiere AA, Metch B, Schuller DE, et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. *J Clin Oncol*. 1992 Aug;10(8):1245-51.
12. Zhang L, Zhang Y, Huang PY, et al. Phase II clinical study of gemcitabine in the treatment of patients with advanced nasopharyngeal carcinoma after the failure of platinum-based chemotherapy. *Cancer Chemother Pharmacol*. 2008;61:33-8. Epub 2007 Mar 20.
13. Martinez-Trufero J, Isla D, Adansa JC, et al. Phase II study of capecitabine as palliative treatment for patients with recurrent and metastatic squamous head and neck cancer after previous platinum-based treatment. *Br J Cancer*

- 2010;102:1687-1691.
14. Al-Sarraf M, Metch B, Kish J, et al. Platinum analogs in recurrent and advanced head and neck cancer: a Southwest Oncology Group and Wayne State University Study. *Cancer Treat Rep* 1987;71:732-736.
 15. Leong S-S, Wee J, Tay MH, et al. Paclitaxel, carboplatin, and gemcitabine in metastatic nasopharyngeal carcinoma: a Phase II trial using a triplet combination. *Cancer*. 2005;103(3):569-575.
 16. Yang Y, Qu S, Li J, et al. Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (captain-1st): A multicentre, randomised, double-blind, phase 3 trial. *Lancet Oncol* 2021;22:1162-1174.
 17. Mai H-Q, Chen Q-Y, Chen D, et al. Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: A multicenter randomized phase 3 trial. *Nat Med* 2021;27:1536-1543.
 18. Yang Y, Qu S, Li J, et al. Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (captain-1st): A multicentre, randomised, double-blind, phase 3 trial. *Lancet Oncol* 2021;22:1162-1174.
 19. Mai H-Q, Chen Q-Y, Chen D, et al. Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: A multicenter randomized phase 3 trial. *Nat Med* 2021;27:1536-1543.

《頭頸癌放射治療共識》

口腔癌

一、治療範圍

1. 口腔腫瘤或腫瘤原發部位
2. 頸部淋巴轉移病灶
3. 頸部高風險淋巴轉移範圍

二、治療劑量 / 次數

1. 總劑量：高劑量區 66~74Gy；中低劑量區 45~63Gy
2. 分次劑量：高劑量區 1.8~2.2Gy；中低劑量區 1.6~2.0Gy

三、治療方式：

使用強度調控放射治療技術，包含弧形及螺旋放射規劃，可考慮搭配影像導引治療，治療選擇可使用同步照射高與低危險部位的方式或先給予整個照射部位部份劑量照射後，再針對高危險部位加強劑量。

四、參考文獻：

1. NCCN clinical practice guidelines in oncology-Head and Neck cancers. version 1, 2025.
2. Adelstein DJ, et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 2003; 21: 92-8
3. Cooper JS, et al. Postoperative concurrent radiation therapy and chemotherapy in high-risk SCCA of the head and neck: The RTOG 9501/Intergroup phase III trial. NEJM 2004; 350(19): 1937-44
4. Bernier J, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. NEJM 2004; 350(19): 1945-52

鼻咽癌

一、治療範圍

1. 鼻咽腫瘤
2. 頸部淋巴轉移病灶
3. 頸部高風險淋巴轉移範圍

二、治療劑量 / 次數

1. 總劑量：高劑量區 69.96~70.2Gy；中低劑量區 44~63Gy
2. 分次劑量：高劑量區 1.8~2.12Gy；中低劑量區 1.6~2.0Gy

三、治療方式：

使用強度調控放射治療技術，包含弧形及螺旋放射規劃，可考慮搭配影像導引治療，治療選擇可使用同步照射高與低危險部位的方式或先給予整個照射部位部份劑量照射後，再針對高危險部位加強劑量。

四、參考文獻：

1. NCCN clinical practice guidelines in oncology-Head and Neck cancers. version 1, 2025.
2. Gregoire V, et al. CT-based delineation of lymph node levels and related CTVs in the node-negative neck: DAHANCA, EORTC, GORTEC, NCIC, RTOG consensus guidelines. Radiother Oncol 2003; 69: 227-36
3. Wolden SL, et al. Intensity-modulated radiation therapy (IMRT) for nasopharynx cancer: update of the Memorial Sloan-Kettering experience. Int J Radiat Oncol Biol Phys 2006; 64: 57-62.

口咽癌

一、治療範圍

1. 口咽腫瘤或腫瘤原發部位
2. 頸部淋巴轉移病灶
3. 頸部高風險淋巴轉移範圍

二、治療劑量 / 次數

1. 總劑量：高劑量區 66~76Gy；中低劑量區 45~66Gy
2. 分次劑量：高劑量區 1.8~2.2Gy；中低劑量區 1.6~2.0Gy

三、治療方式：

使用強度調控放射治療技術，包含弧形及螺旋放射規劃，可考慮搭配影像導引治療，治療選擇可使用同步照射高與低危險部位的方式或先給予整個照射部位部份劑量照射後，再針對高危險部位加強劑量

四、參考文獻：

1. NCCN clinical practice guidelines in oncology for head and neck cancers. Version 1, 2025.
2. Bernier J, Cooper JS, Pajak TF. Defining risk levels in locally advanced head and neck cancers: A comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head & Neck. 27 (10) : 843-50, 2005.
3. Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiation therapy and chemotherapy in high-risk SCCA of the head and neck: The RTOG 9501/Intergroup phase III trial. NEJM. 350 (19) :1937-44, 2004.
4. Bernier J, Dornge C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally head and neck cancer. NEJM. 350 (19) : 1945-52, 2004.

5. Soo KC, Tan EH, Wee J, et al. Surgery and adjuvant radiotherapy vs. concurrent chemoradiotherapy in stage III/IV metastatic squamous cell head and neck cancer: a randomized comparison. *Br J Cancer*. 93 (3) : 279-86, 2005.
6. Hitt R, Lopez-Pousa A, Martinez-Trufero J, et al. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. *J Clin Oncol*. 23: 8636-8645, 2005.
7. QUANTEC Bentzen SM, Constine LS, Deasy JO, et al. Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): an introduction to the scientific issues. *International journal of radiation oncology, biology, physics* 2010; 76(3 Suppl): S3-9.

下咽癌

一、治療範圍

1. 下咽腫瘤或腫瘤原發部位
2. 頸部淋巴轉移病灶
3. 頸部高風險淋巴轉移範圍

二、治療劑量 / 次數

1. 總劑量：高劑量區 66~76Gy；中低劑量區 45~66Gy
2. 分次劑量：高劑量區 1.8~2.2Gy；中低劑量區 1.6~2.0Gy

三、治療方式：

使用強度調控放射治療技術，包含弧形及螺旋放射規劃，可考慮搭配影像導引治療，治療選擇可使用同步照射高與低危險部位的方式或先給予整個照射部位部份劑量照射後，再針對高危險部位加強劑量

四、參考文獻：

1. NCCN clinical practice guidelines in oncology for head and neck cancers. Version 1, 2025.
2. A phase III study of postoperative radiation therapy (IMRT) +/- Cetuximab for locally-advanced resected head and neck cancer. Radiation Therapy Oncology Group, Protocol 0920.
3. Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiation therapy and chemotherapy in high-risk SCCA of the head and neck: The RTOG 9501/Intergroup phase III trial. NEJM. 350 (19):1937-44, 2004.
4. Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. NEJM. 350 (19):1945-52, 2004.
5. Adelstein DJ, Li Y, Adams GL, et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol. 21: 92-8, 2003.

6. Bentzen SM, Constine LS, Deasy JO, et al. Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): an introduction to the scientific issues. International journal of radiation oncology, biology, physics 2010; 76(3 Suppl): S3-9.
7. Thomson DJ, Palma D, Guckenberger M, et al. Practice Recommendations for Risk-Adapted Head and Neck Cancer Radiation Therapy During the COVID-19 Pandemic: An ASTRO-ESTRO Consensus Statement. Int J Radiat Oncol Biol Phys. 107(4):618-627, 2020.